161 related articles for article (PubMed ID: 1373198)
1. Cytotoxicity of a replication-defective mutant of herpes simplex virus type 1.
Johnson PA; Miyanohara A; Levine F; Cahill T; Friedmann T
J Virol; 1992 May; 66(5):2952-65. PubMed ID: 1373198
[TBL] [Abstract][Full Text] [Related]
2. A defective HSV-1 vector expresses Escherichia coli beta-galactosidase in cultured peripheral neurons.
Geller AI; Breakefield XO
Science; 1988 Sep; 241(4873):1667-9. PubMed ID: 2843986
[TBL] [Abstract][Full Text] [Related]
3. The herpes simplex virus gE-gI complex facilitates cell-to-cell spread and binds to components of cell junctions.
Dingwell KS; Johnson DC
J Virol; 1998 Nov; 72(11):8933-42. PubMed ID: 9765438
[TBL] [Abstract][Full Text] [Related]
4. Deletion of the Virion Host Shut-off Gene Enhances Neuronal-Selective Transgene Expression from an HSV Vector Lacking Functional IE Genes.
Miyagawa Y; Verlengia G; Reinhart B; Han F; Uchida H; Zucchini S; Goins WF; Simonato M; Cohen JB; Glorioso JC
Mol Ther Methods Clin Dev; 2017 Sep; 6():79-90. PubMed ID: 28702475
[TBL] [Abstract][Full Text] [Related]
5. HSV.com: maneuvering the internetworks of viral neuropathogenesis and evasion of the host defense.
Tan SL; Katze MG
Proc Natl Acad Sci U S A; 2000 May; 97(11):5684-6. PubMed ID: 10823927
[No Abstract] [Full Text] [Related]
6. Promoting Simultaneous Onset of Viral Gene Expression Among Cells Infected with Herpes Simplex Virus-1.
Ralph M; Bednarchik M; Tomer E; Rafael D; Zargarian S; Gerlic M; Kobiler O
Front Microbiol; 2017; 8():2152. PubMed ID: 29163436
[TBL] [Abstract][Full Text] [Related]
7. Genome-wide CRISPR screen for HSV-1 host factors reveals PAPSS1 contributes to heparan sulfate synthesis.
Suzuki T; Sato Y; Okuno Y; Goshima F; Mikami T; Umeda M; Murata T; Watanabe T; Watashi K; Wakita T; Kitagawa H; Kimura H
Commun Biol; 2022 Jul; 5(1):694. PubMed ID: 35854076
[TBL] [Abstract][Full Text] [Related]
8. Anterograde Neuronal Circuit Tracers Derived from Herpes Simplex Virus 1: Development, Application, and Perspectives.
Li D; Yang H; Xiong F; Xu X; Zeng WB; Zhao F; Luo MH
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32824837
[TBL] [Abstract][Full Text] [Related]
9. Overcoming the blood-brain barrier in neurodegenerative disorders and brain tumours.
Ebrahimi Z; Talaei S; Aghamiri S; Goradel NH; Jafarpour A; Negahdari B
IET Nanobiotechnol; 2020 Aug; 14(6):441-448. PubMed ID: 32755952
[TBL] [Abstract][Full Text] [Related]
10. Herpes Simplex Virus Vectors for Gene Transfer to the Central Nervous System.
Artusi S; Miyagawa Y; Goins WF; Cohen JB; Glorioso JC
Diseases; 2018 Aug; 6(3):. PubMed ID: 30110885
[TBL] [Abstract][Full Text] [Related]
11. Viral Vector Biosafety in Laboratory Animal Research.
Collins DE; Reuter JD; Rush HG; Villano JS
Comp Med; 2017 Jun; 67(3):215-221. PubMed ID: 28662750
[TBL] [Abstract][Full Text] [Related]
12. Toxicity and biodistribution of the serotype 2 recombinant adeno-associated viral vector, encoding Aquaporin-1, after retroductal delivery to a single mouse parotid gland.
Momot D; Zheng C; Yin H; Elbekai RH; Vallant M; Chiorini JA
PLoS One; 2014; 9(3):e92832. PubMed ID: 24667436
[TBL] [Abstract][Full Text] [Related]
13. Activation of H2AX and ATM in varicella-zoster virus (VZV)-infected cells is associated with expression of specific VZV genes.
Yamamoto T; Ali MA; Liu X; Cohen JI
Virology; 2014 Mar; 452-453():52-8. PubMed ID: 24606682
[TBL] [Abstract][Full Text] [Related]
14. Gene delivery with viral vectors for cerebrovascular diseases.
Gan Y; Jing Z; Stetler RA; Cao G
Front Biosci (Elite Ed); 2013 Jan; 5(1):188-203. PubMed ID: 23276981
[TBL] [Abstract][Full Text] [Related]
15. Prospects for the use of artificial chromosomes and minichromosome-like episomes in gene therapy.
Pérez-Luz S; Díaz-Nido J
J Biomed Biotechnol; 2010; 2010():. PubMed ID: 20862363
[TBL] [Abstract][Full Text] [Related]
16. Recognition of virus infection and innate host responses to viral gene therapy vectors.
Shayakhmetov DM; Di Paolo NC; Mossman KL
Mol Ther; 2010 Aug; 18(8):1422-9. PubMed ID: 20551916
[TBL] [Abstract][Full Text] [Related]
17. A limited innate immune response is induced by a replication-defective herpes simplex virus vector following delivery to the murine central nervous system.
Zeier Z; Aguilar JS; Lopez CM; Devi-Rao GB; Watson ZL; Baker HV; Wagner EK; Bloom DC
J Neurovirol; 2009 Sep; 15(5-6):411-24. PubMed ID: 20095947
[TBL] [Abstract][Full Text] [Related]
18. Viral vectors for neurotrophic factor delivery: a gene therapy approach for neurodegenerative diseases of the CNS.
Lim ST; Airavaara M; Harvey BK
Pharmacol Res; 2010 Jan; 61(1):14-26. PubMed ID: 19840853
[TBL] [Abstract][Full Text] [Related]
19. Improved long-term expression from helper virus-free HSV-1 vectors packaged using combinations of mutated HSV-1 proteins that include the UL13 protein kinase and specific components of the VP16 transcriptional complex.
Liu M; Wang X; Geller AI
BMC Mol Biol; 2009 Jun; 10():58. PubMed ID: 19531264
[TBL] [Abstract][Full Text] [Related]
20. Immune responses to herpesviral vectors.
Ryan DA; Federoff HJ
Hum Gene Ther; 2009 May; 20(5):434-41. PubMed ID: 19216681
[No Abstract] [Full Text] [Related]
[Next] [New Search]
